Drugs / SUTIDIAZINE
SUTIDIAZINE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05206201 | Aug 2021 → Jan 2022 | malaria | Zydus Lifesciences Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05911828 Comparator | Aug 2024 → Feb 2025 | Plasmodium falciparum malaria | Zydus Lifesciences Limited | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-12-16 | Zydus Lifesciences Limited | Regulatory Zydus receives Orphan Drug Designation from US FDA for ZY-19489, a novel compound to treat malaria zyduslife.com ↗
Zydus receives Orphan Drug Designation from US FDA for ZY-19489, a novel compound to treat malaria |
| 2021-02-04 | Zydus Lifesciences Limited | Results Zydus announces completion of Phase-I trials of ZY19489A single dose cure for Malaria in collaboration with MMV zyduslife.com ↗
No serious or severe drug-related adverse events were observed. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-16 | Zydus Lifesciences Limited | Zydus receives Orphan Drug Designation from US FDA for ZY-19489, a novel compound to treat malaria zyduslife.com ↗ |
| 2021-02-04 | Zydus Lifesciences Limited | Zydus announces completion of Phase-I trials of ZY19489A single dose cure for Malaria in collaboration with MMV zyduslife.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SUTIDIAZINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4284447 ↗ |
| Known as | MMV253 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4284447 ↗ |
| Known as | Sutidiazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4284447 ↗ |
| Known as | ZY-19489 | “ZY-19489 Administered Via Oral Route” NCT05206201 ↗ |
| Modality | Small molecule | “a triaminopyrimidine” NCT05911828 ↗ |
| Route | Oral | “ZY-19489 Administered Via Oral Route” NCT05206201 ↗ |